Vonoprazan is an oral potassium-competitive acid blocker that has a greater acid-inhibitory effect than proton pump inhibitors (PPIs). Many studies have shown that vonoprazan-based triple therapy had greater efficacy than PPI-based triple therapy for Helicobacter pylori eradication [1]. However, limited information is available on the risk factors for adverse events (AEs) in vonoprazan-besed triple therapy.
